Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day
Company Will Seek An EUA For Baricitinib Plus Remdesivir
Executive Summary
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.
You may also be interested in...
The Secret Sauce To BenevolentAI’s Ongoing Success
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
Can JAK Inhibitors Save Lives From COVID-19? Pfizer Might Let RECOVERY Answer The Question
Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.